Evaluation of Myonectin and Irisin Levels in Pregnant and Non-Pregnant Women

Öz

Objective: To compare serum myonectin and irisin levels between healthy pregnant and non-pregnant women, and to evaluate their relationship with metabolic parameters. Materials and Methods: We conducted a cross-sectional study including 40 pregnant women in their second trimester (between 14 and 28 weeks of gestation) (case group) and 45 healthy non-pregnant women (control group). Fasting blood samples were analyzed for myonectin, irisin, glucose, insulin, and lipid profile. Myonectin and irisin were measured by ELISA. Statistical analyses were performed using SPSS v28, with group comparisons by t-test/Mann–Whitney U, correlations by Spearman’s rho, and diagnostic performance by receiver operating characteristic (ROC) curves. Results: Pregnant women had significantly lower fasting glucose but higher total cholesterol, triglycerides, LDL-C, and HDL-C levels than controls (p<0.05 for all). Serum myonectin and irisin were significantly higher in the pregnant group (p=0.012 and p<0.001, respectively). Myonectin levels correlated negatively with fasting glucose (r=–0.225, p=0.038) and positively with triglycerides (r=0.381, p<0.001). Irisin showed positive correlations with total cholesterol (r=0.348, p=0.001) and triglycerides (r=0.421, p<0.001). In ROC analysis, the discriminatory AUC values for myonectin and irisin levels in pregnancy were found to be 0.689 and 0.806, respectively. Conclusion: Healthy pregnancy is associated with elevated serum myonectin and irisin levels, which correlate with maternal lipid and glucose parameters. These myokines may play an adaptive role in gestational metabolic changes and could serve as metabolic biomarkers in pregnancy.

Anahtar Kelimeler

• Miyonectin
• Irisin
• Myokines
• Pregnancy

Gebelerde ve Gebe Olmayan Kadınlarda Myonektin ve İrisin Düzeylerinin Değerlendirilmesi

Öz

Amaç: Sağlıklı gebeler ile gebe olmayan kadınlarda serum miyonektin ve irisin düzeylerinin farklı olup olmadığını araştırmak ve bu miyokinlerin metabolik parametrelerle ilişkisini değerlendirmektir. Gereç ve Yöntem: Kesitsel bir çalışma kapsamında ikinci trimesterde (gebeliğin 14. ve 28. haftaları arasında) olan 40 hamile kadın (vaka grubu) ve 45 sağlıklı hamile olmayan kadın incelendi. Açlık kan örneklerinde miyonektin, irisin, glukoz, insülin ve lipid profili analiz edildi. Miyonektin ve irisin düzeyleri ELISA yöntemiyle ölçüldü. İstatistiksel analizler SPSS v28 ile yapıldı; gruplar Student t testi veya Mann–Whitney U testi ile karşılaştırıldı, korelasyonlar Spearman analiziyle değerlendirildi ve tanısal performans ROC eğrisi ile incelendi. Bulgular: Gebe grubunda açlık glukozu anlamlı derecede daha düşük, total kolesterol, trigliserid, LDL-K ve HDL-K düzeyleri kontrol grubuna göre daha yüksek bulundu (tümü için p<0.05). Gebelerde serum miyonektin ve irisin düzeyleri kontrol grubundan anlamlı olarak daha yüksekti (sırasıyla p=0.012 ve p<0.001). Miyonektin düzeyi açlık glukoz ile negatif (r=–0.225, p=0.038), trigliserid ile pozitif korelasyon gösterdi (r=0.381, p<0.001). İrisin düzeyi total kolesterol (r=0.348, p=0.001) ve trigliserid (r=0.421, p<0.001) ile pozitif koreleydi. ROC analizinde, miyonektin ve irisin düzeylerinin gebelikte ayırt edici AUC değerleri sırasıyla 0.689 ve 0.806 olarak bulundu. Sonuç: Sağlıklı gebelikte serum miyonektin ve irisin düzeyleri, gebe olmayanlara kıyasla yüksektir ve bu miyokin düzeyleri maternal lipid ve glukoz parametreleriyle ilişkilidir. Bu durum, miyonektin ve irisinin gebelikteki metabolik adaptasyonda rol oynayabileceğini ve gebeliğin metabolik durumunu yansıtan biyobelirteçler olabileceğini düşündürmektedir.

Anahtar Kelimeler

• Miyonektin
• İrisin
• Myokinler
• Gebelik

Kaynakça

1. 1. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88(4):1379–406.
2. 2. Seldin MM, Peterson JM, Byerly MS, Wei Z, Wong GW. Myonectin (CTRP15), a novel myokine, links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012;287(15):11968–80.
3. 3. Safarzade A, Safarpour H. Enhancement of serum myonectin levels by progressive resistance training in rats fed with high-fat diet and sucrose. Zahedan J Res Med Sci. 2021;e108209.
4. 4. P Boström, J Wu, MP Jedrychowski, A Korde, L Ye, JC Lo, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–8.
5. 5. Condorelli RA, Tiranini L, Nappi RE, Calogero AE. The role of irisin throughout women’s life span. Biomedicines. 2023;11(12):3260.
6. 6. Mazur-Bialy AI, Pocheć E, Majewski P. Irisin reduces pro-inflammatory cytokine expression in adipose tissue and attenuates inflammation. J Physiol Pharmacol. 2017;68(5):777–85.
7. 7. Lain KY, Catalano PM. Factors that affect maternal insulin resistance and modify fetal growth and body composition. Metab Syndr Relat Disord. 2006;4(2):91–100.
8. 8. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991–2002.

9. 9. Kuzmicki M, Telejko B, Lipinska D, Pliszka J, Szamatowicz M, Wilk J, et al. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol. 2014;30(9):636–9.
10. 10. Onat T, İnandıklıoğlu N. Circulating myonectin and irisin levels in gestational diabetes mellitus: a case–control study. Z Geburtshilfe Neonatol. 2021;225(4):320–6.
11. 11. Parrettini S, Caroli A, Torlone E. Nutrition and metabolic adaptations in physiological and complicated pregnancy: focus on obesity and gestational diabetes. Front Endocrinol. 2020;11:611929.
12. 12. Petro JL, Gallo-Villegas JA, Calderón JC. Myonectin and metabolic health: a systematic review. Front Endocrinol. 2025;16:1557142.
13. 13. Wang C, Zhang X, Liu M, Qin S, He C, Liu Y, et al. Irisin participates in the beneficial effects of exercise in preventing gestational diabetes mellitus in overweight and obese pregnant women and a mouse model. Front Nutr. 2023;9:1034443.
14. 14. Sultana A, Joarder MAR, Begum K, Shamsunnahar N, Ferdous S, Parveen T. Association of serum irisin with gestational diabetes mellitus. Int J Reprod Contracept Obstet Gynecol. 2025;14(2):379–83.
15. 15. Garcés MF, Peralta JJ, Ruiz-Linares CE, Lozano AR, Poveda NE, Torres-Sierra AL, et al. Irisin levels during pregnancy and changes associated with the development of preeclampsia. J Clin Endocrinol Metab. 2014;99(6):2113–9.
16. 16. Chen Y, Ding J, Zhao Y, Ju S, Mao H, Peng XG. Irisin induces white adipose tissue browning in mice as assessed by magnetic resonance imaging. Exp Biol Med. 2021;246(14):1597–603.
17. 17. Sahoo D, Pattanaik SR, Kumar PR, Gandhi R. Role of serum irisin during early pregnancy to predict the development of gestational diabetes mellitus at 24–28 weeks of pregnancy in high-risk patients. Indian J Endocrinol Metab. 2022;26(1):61–7.
18. 18. Erol O, Erkal N, Ellidağ HY, İsenlik BS, Aydın Ö, Derbent AU, et al. Irisin as an early marker for predicting gestational diabetes mellitus: a prospective study. J Matern Fetal Neonatal Med. 2016;29(22):3590–5.
19. 19. Ural UM, Sahin SB, Tekin YB, Cüre MC, Sezgin H. Alteration of maternal serum irisin levels in gestational diabetes mellitus. Ginekol Pol. 2016;87(5):395–8.
20. 20. Ebert T, Stepan H, Schrey S, Kralisch S, Hindricks J, Hopf L, et al. Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery. Cytokine. 2014;65(2):153–8.